PTH and secondary hyperparathyroidism: Although the doses and duration of the therapies were similar in all of the patients in our study, high serum levels in the patients with elevated serum PTH and FGF-23 levels could be insufficient in suppression of PTH secretion and resulted in the development of secondary hyperparathyroidism.